Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 17;17(12):2019.
doi: 10.3390/cancers17122019.

Fluorescence Guidance in Glioma Surgery: A Narrative Review of Current Evidence and the Drive Towards Objective Margin Differentiation

Matthew Elliot  1   2 , Silvère Ségaud  1 , Jose Pedro Lavrador  2 , Francesco Vergani  2 , Ranjeev Bhangoo  2 , Keyoumars Ashkan  1   2 , Yijing Xie  1 , Graeme J Stasiuk  3 , Tom Vercauteren  1 , Jonathan Shapey  1   2
Affiliations
Review

Fluorescence Guidance in Glioma Surgery: A Narrative Review of Current Evidence and the Drive Towards Objective Margin Differentiation

Matthew Elliot et al. Cancers (Basel). .

Abstract

Fluorescence-guided surgery (FGS) was pioneered for glioma and is now established as the standard of care. Gliomas are infiltrative tumours with diffuse margins. FGS provides improved intra-operative identification of tumour margins based on tumour-specific emission visible to the operating surgeon, resulting in increased rates of gross total resection. Multiple fluorescence agents may be used including 5-ALA, fluorescein sodium, and indocyanine green (ICG). This review details the indication, required equipment, mechanism of action, evidence base, limitations, and regulatory issues for each fluorophore as utilised in current clinical practice. FGS for glioma is limited by a reliance on subjective interpretation of visible fluorescence, which is often not present in low-grade glioma (LGG) or at the infiltrative tumour margin. Consequently, there has been a drive to develop enhanced, objective FGS techniques utilising both quantitative fluorescence (QF) imaging systems and novel fluorophores. This review provides an overview of emerging QF imaging systems for FGS. The pipeline for novel fluorophore development is also summarised.

Keywords: 5-ALA; ICG; PpIX; fluorescein; fluorescence; fluorescence-guided surgery; glioma; quantitative fluorescence.

PubMed Disclaimer

Conflict of interest statement

J.S. and T.V. are shareholders and co-founders of Hypervision Surgical Ltd., a King’s College London spinout company developing hyperspectral technology for surgical use. Hypervision surgical had no role in the review design, interpretation of data, or writing of this manuscript.

Figures

Figure 1
Figure 1
5-ALA fluorescence-guided surgery. (a) White-light visualisation of glioblastoma involving cortical surface. (b) Surgical field under blue (405 nm) light, demonstrating avid red/pink tumour fluorescence. (c) White-light visualisation of WHO Grade 2 oligodendroglioma involving cortical surface. (d) Blue-light imaging, demonstrating lack of visible tumour fluorescence. Images courtesy of Neuro PPEye study team, King’s College London, UK (NCT05397574).
Figure 2
Figure 2
Simplified schematic of PpIX synthesis in heme biosynthetic pathway. ABCG2: ATP-binding cassette G2; ABCB6: ATP-binding cassette B6; CPOX: coproporphyrinogen oxidase; PPOX: protoporphyrinogen oxidase.
Figure 3
Figure 3
Fluorescein fluorescence guided surgery (a) White-light visualisation of infiltrated gyrus. (b) Surgical field under yellow (560 nm) light, demonstrating green fluorescence at areas of tumour infiltration. Images courtesy of Mr Ryan Mathew, University of Leeds, UK.
Figure 4
Figure 4
ICG angiography during glioma surgery. (a) White-light visualisation of resection cavity showing skeletonized cortical and tumour associated vessels. (b) IR imaging of surgical field with 800 nm excitation light, demonstrating abnormal tumour vessels and preserved flow in overlying cortical vessels. Images courtesy of Neuro PPEye study team, King’s College London, UK (NCT05397574).
Figure 5
Figure 5
Chemical structures and optical emission spectra of key fluorophores used in, and under investigation for, glioma FGS [188]. Excitation spectra are shown in blue, and emission spectra are shown in red. IRDye800CW spectra courtesy of Mr Jean-Romain Lotthe, Kings College London.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Chaichana K.L., Jusue-Torres I., Navarro-Ramirez R., Raza S.M., Pascual-Gallego M., Ibrahim A., Hernandez-Hermann M., Gomez L., Ye X., Weingart J.D., et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncol. 2014;16:113–122. doi: 10.1093/neuonc/not137. - DOI - PMC - PubMed
    1. Hervey-Jumper S.L., Berger M.S. Role of surgical resection in low- and high-grade gliomas. Curr. Treat. Options Neurol. 2014;16:284. doi: 10.1007/s11940-014-0284-7. - DOI - PubMed
    1. Plaha P., Camp S., Cook J., McCulloch P., Voets N., Ma R., Taphoorn M.J., Dirven L., Grech-Sollars M., Watts C., et al. FUTURE-GB: Functional and ultrasound-guided resection of glioblastoma—A two-stage randomised control trial. BMJ Open. 2022;12:e064823. doi: 10.1136/bmjopen-2022-064823. - DOI - PMC - PubMed

LinkOut - more resources